| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
310,240,000 |
| Market
Cap: |
6.79(B) |
| Last
Volume: |
1,303,478 |
Avg
Vol: |
2,431,686 |
| 52
Week Range: |
$18.78 - $24.13 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 17.5 |
| Insider 6 Months : 18.9 |
| Insider 3/6 Months : 36.8 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
425,000 |
615,000 |
735,409 |
735,409 |
| Total Buy Value |
$8,733,955 |
$12,666,689 |
$15,268,727 |
$15,268,727 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
2 |
3 |
4 |
4 |
| Total Shares Sold |
88,818 |
224,987 |
601,659 |
1,021,249 |
| Total Sell Value |
$1,938,121 |
$5,007,803 |
$12,908,109 |
$20,266,173 |
| Total People Sold |
5 |
7 |
9 |
12 |
| Total Sell Transactions |
6 |
10 |
17 |
28 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Marchesi Vincent T |
Director |
– • – |
2020-05-21 |
4 |
S |
$24.64 |
$985,600 |
D/D |
(40,000) |
90,212 |
|
5% |
|
| Marchesi Vincent T |
Director |
– • – |
2020-05-21 |
4 |
OE |
$5.82 |
$232,800 |
D/D |
40,000 |
130,212 |
|
- |
|
| Marchesi Vincent T |
Director |
– • – |
2020-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
7,728 |
90,212 |
|
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2020-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
15,538 |
1,188,897 |
|
- |
|
| Poste George |
Director |
– • – |
2020-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
15,538 |
128,330 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2020-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
7,728 |
169,406 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2020-05-20 |
4 |
AS |
$24.99 |
$78,743 |
D/D |
(3,151) |
115,340 |
|
-2% |
|
| Morrissey Michael M |
President and CEO |
• • – |
2020-05-19 |
4 |
GA |
$0.00 |
$0 |
I/I |
35,935 |
889,574 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2020-05-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
35,935 |
85,985 |
|
- |
|
| Scangos George A |
Director |
– • – |
2020-05-18 |
4 |
AS |
$25.96 |
$1,947,000 |
D/D |
(75,000) |
714,717 |
|
-11% |
|
| Willsey Lance |
Director |
– • – |
2020-05-18 |
4 |
S |
$26.26 |
$787,800 |
D/D |
(30,000) |
368,273 |
|
11% |
|
| Willsey Lance |
Director |
– • – |
2020-05-18 |
4 |
OE |
$4.58 |
$137,400 |
D/D |
30,000 |
398,273 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2020-05-15 |
4 |
D |
$25.76 |
$1,650,314 |
D/D |
(64,065) |
121,920 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2020-05-15 |
4 |
OE |
$6.21 |
$621,000 |
D/D |
100,000 |
185,985 |
|
- |
|
| Scangos George A |
Director |
– • – |
2020-05-15 |
4 |
OE |
$4.58 |
$263,613 |
D/D |
51,686 |
789,717 |
|
- |
|
| Willsey Lance |
Director |
– • – |
2020-05-14 |
4 |
S |
$25.26 |
$378,900 |
D/D |
(15,000) |
368,273 |
|
12% |
|
| Willsey Lance |
Director |
– • – |
2020-05-14 |
4 |
OE |
$5.92 |
$88,800 |
D/D |
15,000 |
383,273 |
|
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2020-05-13 |
4 |
OE |
$5.82 |
$703,004 |
D/D |
120,791 |
1,173,359 |
|
- |
|
| Hessekiel Jeffrey |
EVP and General Counsel |
• – – |
2020-05-13 |
4 |
D |
$26.53 |
$368,104 |
D/D |
(13,875) |
250,313 |
|
- |
|
| Hessekiel Jeffrey |
EVP and General Counsel |
• – – |
2020-05-13 |
4 |
OE |
$1.70 |
$42,500 |
D/D |
25,000 |
264,188 |
|
- |
|
| Marchesi Vincent T |
Director |
– • – |
2020-05-11 |
4 |
S |
$26.30 |
$789,000 |
D/D |
(30,000) |
82,484 |
|
6% |
|
| Marchesi Vincent T |
Director |
– • – |
2020-05-11 |
4 |
OE |
$4.58 |
$137,400 |
D/D |
30,000 |
112,484 |
|
- |
|
| Hessekiel Jeffrey |
EVP and General Counsel |
• – – |
2020-05-11 |
4 |
S |
$27.09 |
$1,029,583 |
D/D |
(38,006) |
239,188 |
|
6% |
|
| Hessekiel Jeffrey |
EVP and General Counsel |
• – – |
2020-05-11 |
4 |
OE |
$1.90 |
$72,211 |
D/D |
38,006 |
277,194 |
|
- |
|
| Hessekiel Jeffrey |
EVP and General Counsel |
• – – |
2020-05-08 |
4 |
S |
$26.04 |
$651,000 |
D/D |
(25,000) |
239,188 |
|
-3% |
|
985 Records found
|
|
Page 17 of 40 |
|
|
0.30 (1.35%) 
